Marketing applications in the U.S. for experimental treatments that use new molecular entities increased by 33% in 2007, according to a report from PAREXEL International. The study, however, also found that approvals for such drug candidates "reached a many-year low of 16." NME approvals are a key measure of new drug productivity and tend to increase based on the number of new drug submissions, said Mark Mathieu, PAREXEL's director of publications.

Related Summaries